# ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)

> **NCT04453839** · — · NO_LONGER_AVAILABLE · sponsor: **APR Applied Pharma Research s.a.**

## Conditions studied

- Critical COVID-19 With Respiratory Failure

## Interventions

- **DRUG:** ZYESAMI (aviptadil acetate)

## Key facts

- **NCT ID:** NCT04453839
- **Lead sponsor:** APR Applied Pharma Research s.a.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04453839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04453839, "ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT04453839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*